SAB Biotherapeutics IncNASDAQ:SABS
- LAST PRICE4.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.1300/ 10
- Ask / Lots5.0000/ 3
- Open / Previous Close0.0000 / 4.4000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SABS |
|---|---|---|
| 12:25 ET | 100 | 4.4001 |
| 12:30 ET | 100 | 4.4 |
| 03:38 ET | 137 | 4.4 |
Apr 16, 2024
DJ SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co., from 1:38PM ET on Tuesday Apr 16, 2024 by Dow Jones
1:38PM ET on Tuesday Apr 16, 2024 by Dow JonesDJ SAB Biotherapeutics Is Maintained at Buy by Chardan Capital, from 7:52AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:52AM ET on Tuesday Apr 16, 2024 by Dow JonesSAB Biotherapeutics Provides SAB-142 Trial Update, from 7:15AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:15AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 8, 2024
SAB Biotherapeutics to Present at INNODIA Annual Meeting, from 7:15AM ET on Monday Apr 08, 2024 by Dow Jones
7:15AM ET on Monday Apr 08, 2024 by Dow Jones
Apr 4, 2024
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference, from 7:15AM ET on Thursday Apr 04, 2024 by Dow Jones
7:15AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SAB Biotherapeutics Inc | 40.6M | -0.6x | --- |
Dyadic International Inc | 43.5M | -6.4x | --- |
Marker Therapeutics Inc | 39.2M | -2.8x | --- |
Matinas BioPharma Holdings Inc | 45.6M | -1.7x | --- |
Clene Inc. | 43.3M | -0.6x | --- |
Estrella Immunopharma Inc | 41.0M | -0.6x | --- |
Company Information
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
Contact Information
- Headquarters
- 2100 East 54Th Street North, Suite 202SIOUX FALLS, SD, United States 57104
- Phone
- 605-679-6980
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board, Chief Executive Officer
- Samuel Reich
- President, Director
- Eddie Sullivan
- Non-Executive Independent Vice Chairman of the Board
- David Link
- Chief Financial Officer
- Michael King
- Chief Operating Officer
- Christoph Bausch
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $40.6M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 9.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-7.18 |
Book Value | $6.21 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 18.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,700.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
